Background {#Sec1}
==========

Cancer is a multifactorial disease resulted from complex interactions between genetic and environmental and its worldwide burden is increasing \[[@CR1]\]. Reactive oxidative stress (ROS) is showed to play a significant role in immunological defense, intracellular signaling, and intercellular communication \[[@CR2]\]. An increased ROS is considered to be mutagenic and carcinogenic, and it may result in cell damage and alterations of the cell proliferation and apoptosis mechanism, thus contributing to cancer development \[[@CR3]\].

Myeloperoxidase (MPO) is an endogenous metabolic/oxidative lysosomal enzyme secreted by reactive neutrophils and monocytes. MPO plays an important role in carcinogenesis through activating procarcinogens to genotoxic intermediates and potentiation of xenobiotic carcinogenicity \[[@CR4]\]. The MPO-463G \> A polymorphism is located in the promoter region of MPO gene and is most extensively studied. This polymorphism may influence the MPO transcription level through removing a binding region for transcription factor Sp1, which can decrease the metabolic activation of carcinogenic compounds. Studies suggested that the MPO A allele carriers were associated with lower mRNA expression and transcription activity than the 463 G common allele \[[@CR5]--[@CR7]\]. Abundant studies were conducted to investigate the role of this polymorphism in cancer development, including lung cancer, breast cancer, ovary cancer, gastric carcinoma and others, but results were inconsistent.

For instance, the association between MPO-463G \> A polymorphism and lung cancer risk has attracted the most attention since the first meta-analysis performed in 2002 and suggested a slight protective effect of the MPO 463 A variant \[[@CR8]\]. But research results in the following years varied a lot. Whether MPO-463G \> A polymorphism could be a good predictor of cancer remained controversial. Up to 2010, a meta-analysis gave a systematic review into the association between MPO-463G \> A polymorphism and cancer risk, including breast cancer, leukemia, and lung cancer \[[@CR9]\]. This analysis did not report a significant association between these cancers and MPO-463G \> A polymorphism, but suggested a moderately protective effect on cancer risk in Europeans. After that, many new studies attempted to further describe this association emerged, but came up with different results \[[@CR10], [@CR11]\].

In consideration of the recently published studies and the absence of a new systematic and comprehensive evaluation for the association between MPO-463G \> A polymorphism and cancer risk, we conducted this meta-analysis to shed a light on this relationship.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

Eligible literatures published before December 2015 were identified by searching PubMed, Cochrane Clinical Trials Database, Medline, EMBASE Google Scholar, and the Ovid Library with the following keywords: "Myeloperoxidase", "MPO", "polymorphism," or "variant" without any restriction on language. The scope of computerized literature search was expanded according to the reference lists of retrieved articles. The relevant original articles were also retrieved manually.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Any observational studies met the following criteria were included: (a) a study related to the MPO-463G \> A polymorphism and cancer risk, (b) a case-control study, (c) the data of genotype frequency was available. Major reasons for exclusion of studies were as follows: (a) the use of only case-group data, (b) the duplication or overlap of previous publication, (c) the Newcastle-Ottawa Scale (NOS) score is less than 5 stars, and (d) familial type of cancer.

Data extraction {#Sec5}
---------------

After removing duplicate studies, two investigators extracted the data individually from the reserved studies, and a third investigator was involved when discrepancies were raised. From each study, the following information was extracted: first author, journal, year of publication, country, ethnicity (Caucasian, Asian, and others), cancer type, source of controls (hospital-based studies, population-based studies), identification of cancer cases, genotyping methods, and the number of cases and controls for MPO-463G \> A polymorphism.

Quality assessment {#Sec6}
------------------

The Newcastle-Ottawa Scale (NOS) is a star rating system used to assess the study quality. The full score is defined as 9 stars, and 0 to 4 stars are usually considered to be a poor methodological quality while 5 to 9 stars are considered to be high quality. Any disagreements on the NOS score of these studies were solved by discussion and only studies with high quality were included.

Statistical analysis {#Sec7}
--------------------

The frequencies of the alleles and distributions of the genotypes of MPO-463G \> A polymorphism in control groups were tested for Hardy-Weinberg equilibrium (HWE) using *X* ^2^ test. Odds ratios (OR) and 95% confidence intervals (95%CI) were used to assess the strength of associations between MPO-463G \> A polymorphism and cancer risk. The combined ORs were calculated for dominant model (AA/GA versus GG), recessive model (AA versus GA/GG), additive model (AA versus GG), and allele frequency model (A versus G) to assume the effects of the variant A allele, respectively. Stratified analyses were also conducted by cancer types, ethnicity, HWE, and source of controls.

The heterogeneity between studies was tested using the *Q*-statistic. *I* ^2^ metrics was used to determine the impact of heterogeneity and it was considered moderately when *I* ^2^ \< 50%, and a fixed-effects model was utilized. Heterogeneity was considered statistically significant when *I* ^2^ \> 50% and a random-effects model was employed to calculate the pooled ORs \[[@CR12]\]. Sensitivity analysis was carried out to evaluate the influence of individual study by excluding each study at a time. Publication bias was investigated with funnel plots and Egger's tests qualitatively. In addition, in order to evaluate the trend in OR over time, cumulative meta-analysis was performed. All statistical analyses were performed using STATA 11.2 statistical software.

Results {#Sec8}
=======

Literature search results and studies characteristics {#Sec9}
-----------------------------------------------------

After a comprehensive literature search, 1124 independent studies were preliminarily found. After excluding the uncorrelated and duplicate articles, 91 articles were included. Through reading the full texts, we further excluded 31 articles. Among them, 6 were not about MPO-463G \> A polymorphisms, 11 had overlapping data, 4 did not report available data, 9 were meta-analyses, and 1 was not a case-control study. Therefore, the current meta-analysis included data from 60 articles that consisted of 38,614 subjects (16,858 cases and 21,756 controls). Figure [1](#Fig1){ref-type="fig"} provides a summary of the selection process.Fig. 1Flow chart illustrating the identification, screening, eligibility, and inclusion of studies on MPO-463G \> A polymorphism and cancer risk

Table [1](#Tab1){ref-type="table"} shows a list of details of studies included in the current meta-analysis. The included articles comprised 25 lung cancer studies \[[@CR8], [@CR13]--[@CR36]\], 5 breast cancer studies \[[@CR37]--[@CR41]\], 12 digestive system studies (gastrointestinal cancer: 3 esophagus studies, 3 stomach studies, and 2 colorectum studies; cancer of digestive organs: 3 liver studies, 1 pancreas studies) \[[@CR42]--[@CR53]\], 7 blood system studies (3 acute leukemia studies, 3 lymphoma studies, 1 multiple myeloma, and chronic granulocytic leukemia studies) \[[@CR54]--[@CR60]\] and 14 other studies ( 3 head and neck cancer studies, 3 gynecological tract cancer studies, 3 urological cancer studies, 2 musculoskeletal cancer studies, and 3 mix cancer studies) \[[@CR14], [@CR34], [@CR61]--[@CR71]\]. Cancers referred in the mix cancer studies included lung cancer, laryngeal cancer, and pharyngeal cancer \[[@CR14]\]; lung cancer, prostate cancer \[[@CR34]\]; multiple myeloma, and chronic granulocytic leukemia \[[@CR58]\]. If the ethnicity was clearly described in the original studies, the studies would be categorized to the corresponding ethnicity group. If the original studies have not given a clear indication of ethnicity, the studies were categorized according to research region. If it has been specified in the original studies that the objects included were from different ethnicities, then studies should be categorized to the mix ethnicity group. Of the 60 studies, 24 were Asian background, 32 were Caucasian background, and 4 were mixed population background. Besides, the detailed description of hospital controls was addressed in Table [4](#Tab4){ref-type="table"}.Table 1Overview of studies included in the current meta-analysisAuthorYearCountryEthicsCancerDisease confirmedResourceCaseControlGenotypingNOS scoreLondon1997Americamix EthicsLung cancerNAPB339703RT-PCR7Marchand2000Americamix EthicsLung cancerHistologicalPB323437PCR-RFLP8Misra2001FinlandCaucasianLung cancerHistologicalPB315311PCR-RFLP8Xu2002AmericaCaucasianLung cancerHistologicalHB9891128PCR-RFLP7Lv2002ChinaAsianLung cancerHistologicalPB314320PCR8Kantarct2002AmericaCaucasianLung cancerNAHB307307NA5Feyler2002FranceCaucasianLung cancerHistologicalHB150172capillary PCR7Dally2002GermanyCaucasianLung cancerNAHB625340PCR-RFLP.6Chevriera2003FranceCaucasianLung cancerHistologicalHB243245PCR-RFLP7Skuladottira2004DenmarkCaucasianLung cancerNAPB122396NA6Chana2004ChinaAsianLung cancerNAHB75162PCR-RFLP6Harms2004AmericaCaucasianLung cancerPathologicalPB110119MALDI-TOF8Wu2004ChinaAsianLung cancerHistologicalPB98112PCR8Schabath2005AmericaCaucasianLung cancerHistologicalHB837618PCR-RFLP7Park2006KoreaAsianLung cancerHistologicalHB432432PCR-RFLP7Larsen2006AustraliaCaucasianLung cancerCytological or histologicalHB627624PCR7Yanga2007KoreanAsianLung cancerHistologicalHB318353PCR-RFLP7Zienolddiny2008NorwayCaucasianLung cancerPathologistsPB258297NA7Yoon2008KoreaAsianLung cancerHistologicalHB213213Taqman probe7Rotunno2009AmericaCaucasianLung cancerHistologyPB1852011NA7Klinchid2009ThailandAsianLung cancerHistologicalHB8881PCR-RFLP7Kiyohara2014JapanAsianLung cancerHistologicalHB462379TaqMan7Bag2014IndiaAsianLung cancerTissue diagnosisHB2637PCR-RFLP7Cascorbi2000GermanyCaucasianMixNAPB696270PCR-RFLP7Arslan2011TurkeyCaucasianMixHistologicalHB220418PCR-RFLP7Lin2004TaiwanAsianBreast cancerMedical charts and pathologyPB99366PCR-RFLP8Ahn2004CanadaCaucasianBreast cancerNAPB10111067PCR-RFLP.7Yang2007AmericaCaucasianBreast cancerNAPB406392PCR-RFLP7Li2009AmericaCaucasianBreast cancerNANA477462PCR-RFLP.5Tsai2012TaiwanAsianBreast cancerNANA260224PCR-RFLP5Zhang2007ChinaAsianAcute leukemiaFrench-American-British criteriaHB135187Taqman7Krajinovic2002CanadaCaucasianALLHematology-oncologyHB169337PCR-RFLP7Silveira2010Brazilmix EthicsALLImmunophenotypingNA124300PCR-RFLP6Matsuo2001JapanAsianLymphomaHistologicalHB372241PCR-RFLP7Saygilii2009TurkeyCaucasianMixNAHB6240TaqMan6Wang2006AmericaCaucasianNHLHistopathologyPB1082905NA7Farawela2012EgyptAsianNHLBiopsyHB100100RT-PCR7Funke2009GermanyCaucasianColorectal cancerNAPB627603PCR7Li2011ChinaAsianColorectal cancerHistologicalHB325345PCR-RFLP7Matsuo2001JapanAsianEsophageal cancerNAHB91241PCR-RFLP6Li2008ChinaAsianEsophageal cancerPathologistsPB126169PCR-RFLP8Li2011ChinaAsianEsophageal cancerHistopathologicHB94280NA6Zhu2006ChinaAsianGastric cancerBiopsy or surgical specimensNA127139PCR-RFLP6Wang2011ChinaAsianGastric cancerPathologicalHB6261ASP-PCR7Jang2012ChinaAsianGastric cancerPathologicalHB117105PCR-RFLP7Pakakasama2003AmericaCaucasianHepatoblastomaPCR-SSCPPB48180Pyrosequencing7Nahon2011FranceCaucasianHepatocellular cancerBarcelona criteriaHB84121NA6Carmo2012BrazilCaucasianHepatocellular cancerAASLD guidelinesHB32252PCR-amplified7Mustea2007GermanyCaucasianCervical cancerHistologicalHB149126PCR-RFLP7Olson2004AmericaCaucasianOvarian cancerNAPB122179TaqMan7CastilloTong2014AustriaCaucasianOvarian cancerHistopathologicalNA305299TaqMan probes6Hung2004ItalyCaucasianBladder cancerHistologicalHB201214PCR-RFLP7Hsieh2010TaiwanAsianLeiomyomaPathologicalHB158156PCR-RFLP7Guo2010ChinaAsianNasopharyngeal carcinomaBiopsyHB358629PCR-RFLP7Wu2010TaiwanAsianOral cavityPathologicalHB122122PCR7Oliveira2007Brazilmix EthicsOsteosarcomaNAHB78157PCR-RFLP6Price2008CanadaCaucasianPancreatic cancerHistologicalHB122331PCR7Buch2008AmericaCaucasianSquamous cell carcinomaBiopsy-verifiedPB193414PCR-RFLP8Choi2008AmericaCaucasianProstate cancerPathologyHB4931332NA6Tefik2013TurkeyCaucasianProstate cancerHistologicalHB155195PCR7*NA* not available, *ALL* acute lymphoblastic leukemia, *NAL* non-Hodgkin lymphoma, mix: 2 or more cancer type, *PB* population base, *HB* hospital base, *PCR-RFLP* polymerase chain reaction restriction fragment length polymorphism, *RT-PCR* real-time polymerase chain reaction

Quantitative synthesis {#Sec10}
----------------------

In total, significant association between MPO-463G \> A polymorphism and cancer risk was observed under all the selected models when the eligible results were pooled together (Fig. [2](#Fig2){ref-type="fig"}). Results promoted that the mutant allele A and genotypes of AA as well as AA + GA might played protective roles in the development of cancer (AA versus GG: OR = 0.84, 95%CI = 0.76--0.94; A versus G: OR = 0.90, 95%CI = 0.84--0.95; AA versus AG/GG: OR = 0.87, 95%CI = 0.78--0.97; AA/AG versus GG: OR = 0.89, 95%CI = 0.83--0.95). The pooled results are summarized in Table [2](#Tab2){ref-type="table"}.Fig. 2Forest plots of meta-analysis of MPO-463G \> A polymorphism in association with cancer risk (AA vs. GG) Table 2Stratified analyses of the MPO-463G \> A polymorphism on cancer risk by cancer typeStudy groupsA vs. GAA vs. GGAA vs. AG + GGAA + AG vs. GGOR (95%CI)*I* ^2^OR (95%CI)*I* ^2^OR (95%CI)*I* ^2^OR (95%CI)*I* ^2^Total0.90(0.84--0.95)0.5710.84(0.76--0.94)0.4170.87(0.78--0.97)0.3660.89(0.83--0.95)0.520Lung0.92(0.83--1.01)0.5250.93(0.78--1.10)0.4810.95(0.80--1.12)0.4880.93(0.87--0.99)0.420Breast0.98(0.83--1.16)0.5450.99(0.75--1.30)0.4411.00(0.76--1.32)0.3420.96(0.85--1.08)0.418Digestive0.71(0.57--0.87)0.6940.63(0.37--1.05)0.5290.77(0.57--1.02)0.4150.67(0.53--0.84)0.619Dig tract0.75(0.59--0.95)0.6680.74(0.39--1.43)0.5230.92(0.65--1.29)0.4490.72(0.56--0.92)0.577Dig gland0.63(0.40--0.98)0.7000.41(0.23--0.72)0.3550.51(0.29--0.89)0.0000.58(0.35--0.96)0.649Blood1.12(0.96--1.25)0.4310.96(0.63--1.58)0.5011.03(0.85--1.40)0.6231.03(0.85--1.40)0.623

Stratified by cancer type {#Sec11}
-------------------------

According to the cancer type, when the minimum number of studies is greater than or equal to 5, we combined the studies and conducted stratified analysis. Considering that gastrointestinal and digestive organs all belong to digestive system and might be affected by similar factors such as dietary factors, we grouped them together as digestive system cancer group. In the digestive system cancer group, significant association was seen in the allele frequency model (OR = 0.71, 95%CI = 0.57--0.88) and the dominant model (OR = 0.67, 95%CI = 0.53--0.84). In order to further discuss the cancer risk of MPO-463G \> A polymorphism, we divided digestive system cancer into digestive tract and digestive gland cancer. The results showed that allele A of MPO-463G \> A was significant with a decreased risk of digestive gland cancer in all the genetic models (A versus G: OR = 0.63, 95%CI = 0.40--0.99; AA versus GG: OR = 0.41, 95%CI = 0.23--0.73; AA versus AG/GG: OR = 0.51, 95%CI = 0.29--0.89; AA/AG versus GG: OR = 0.58, 95%CI = 0.35--0.96) and digestive tract cancers (A versus G: OR = 0.75, 95%CI = 0.59-0.95; AA/AG versus GG:OR = 0.72, 95%CI = 0.56--0.92). Besides, in the lung cancer group, statistically significant finding was only observed in dominant model (OR = 0.93, 95%CI = 0.87--0.99). While, among studies of breast cancer and blood system cancer, no significant association was found in any genetic model.

Stratified by ethnicity {#Sec12}
-----------------------

In terms of ethnicity, we divided the ethnicity into three groups: Caucasian group, Asian group, and mix ethnicity group. The current result demonstrated that the genotype A may be a protect factor for both Caucasians and Asians, but not for mix ethnicity group. The different result from previous meta-analyses is seen in Table [3](#Tab3){ref-type="table"}.Table 3Stratified analyses of the MPO-463G \> A polymorphism on cancer risk by ethnicity and source of control groupVariablesA vs. GAA vs. GGAA vs. AG + GGAA + AG vs. GGOR (95%CI)*I* ^2^OR (95%CI)*I* ^2^OR (95%CI)*I* ^2^OR (95%CI)*I* ^2^ Total0.90(0.854-1.069)0.5710.84(0.76-0.94)0.4170.89(0.83-0.95)0.5200.87(0.78-0.97)0.366Ethnicity Caucasian0.90(0.84--0.97)0.5760.85(0.76--0.96)0.5060.91(0.84--0.98)0.5330.87(0.78--0.98)0.484 Asian0.86(0.75--0.98)0.5970.75(0.57--0.98)0.3530.84(0.73--0.96)0.5160.80(0.61--1.05)0.242 Other1.05(0.86--1.27)0.0001.03(0.64--1.67)0.0001.08(0.85--1.37)0.0000.98(0.61--1.57)0.000Lung cancer Caucasian0.956(0.84--0.97)0.5241.082(0.888--1.319)0.5731.050(0.749--1.472)0.5930.950(0.878--1.029)0.420 Asian0.863(0.691--1.078)0.5510.641(0.370--1.110)0.0130.709(0.400--1.256)0.0000.861(0.740--1.002)0.495 Other0.861(0.715--1.037)0.1760.567(0.363--0.886)0.0000.558(0.360--0.867)0.0000.926(0.758--1.132)0.467Digestive Cancer Caucasian0.704(0.474--1.045)0.7960.609(0.291--1.274)0.6200.751(0.514--1.100)0.4280.658(0.423--1.024)0.756 Asian0.706(0.537--0.928)0.6130.640(0.271--1.512)0.5330.785(0.507--1.215)0.4910.669(0.512--0.875)0.474Resource Population0.91(0.83--0.99)0.5410.90(0.77--1.05)0.4530.91(0.81--1.01)0.5180.91(0.78--1.06)0.461 Hospital0.89(0.81--0.98)0.6030.79(0.68--0.93)0.4000.88(0.80--0.98)0.5430.83(0.71--0.96)0.301 Others0.86(0.69--1.08)0.6250.87(0.57--1.33)0.5250.86(0.68--1.08)0.5030.90(0.59--1.36)0.111HWE Yes0.89(0.83--0.96)0.5980.88(0.77--0.96)0.4540.88(0.81--0.95)0.5070.92(0.81--1.04)0.373 No0.91(0.81--1.02)0.4340.75(0.61--0.93)0.1670.93(0.79--1.10)0.6070.74(0.60--0.91)0.297

When further stratified, the digestive system cancer subgroup by ethnicity, no significant association between MPO-463G \> A polymorphism and Caucasians was found in any genetic model. Conversely, for the lung cancer subgroup, there was no significant association between MPO-463G \> A polymorphism and Asians (Table [3](#Tab3){ref-type="table"}).

Stratified by HWE {#Sec13}
-----------------

Not all the studies included in this current analysis conformed to HWE. When stratified, in the HWE balanced group, the MPO-463G \> A polymorphism was significantly associated with cancer risk in all the genetic models, while in the HWE un-balanced group, this association was only found in the recessive model and additive model. Results were represented in Table [2](#Tab2){ref-type="table"}.

Stratified by source of control group {#Sec14}
-------------------------------------

When it was stratified according to the source of control group, a statistically significant finding was found among hospital controls (A versus G: OR = 0.892, 95%CI = 0.811--0.981; AA versus GG: OR = 0.79, 95%CI = 0.68--0.93; AA/AG versus GG : OR = 0.88, 95%CI = 0.80--0.97; AA versus AG/GG: OR = 0.83, 95%CI = 0.71--0.96), but no statistically significant evidence was found in controls based on population under most of the selected gene models except allele frequency model (OR = 0.91, 95%CI = 0.83--0.97) (Table [4](#Tab4){ref-type="table"}).Table 4The hospital control's detailsAuthorYeardetailsMatsuo2001Outpatients without any history of cancerMatsuo2001Non-cancer controlsXu2002Friends or spouses of patients (with either lung cancer or other cardiothoracic problems), with no matching characteristicsKrajinovic2002Selected from a large institutional DNA bank. Care was taken to match the patient population by selecting controls of French-Canadian origin served by Sainte-Justine HospitalKantarct2002Without diagnosis of lung cancerFeyler2002Frequency matched on age, sex, and hospital, consisted of all consecutive Caucasian patients without previous or current malignant diseasesDally2002Had no previous or present history of malignant diseases: the main diagnoses included alveolitis, bronchitis,pneumonia, fibrosis,sarcoidosis, COPD and emphysemaChevriera2001All subjects hospitalized for different disorders except cancerChana2004Had no history of pulmonary diseases, and were receiving health evaluation for other reasons and matched for sex and age with the lung cancer patientsHung2004Patients admitted to the same hospitals during the same period of time, with urological non-neoplastic diseases, including hydronephrosis, urolithiasis, malformative urological diseases, prostatic adenoma, and hypertrophia, urological traumas, orchiepididymitis, hydrocele and unspecified urinary symptomsSchabath2005Healthy controls frequency matched to the cases on age (±5 years), gender,ethnicity, and smoking status (current, former, and never)Park2006Healthy volunteersLarsen2006Controls consisted of patients with chronic obstructive pulmonary disease (COPD) but without lung cancer (*n* ¼ 380), treated at the same hospital from 1998 to 2003, or healthy smokers attending a smoking cessation clinic held at the hospital from 2000 to 2003Zhang2007No known malignant diseasesYanga2007Healty individuals without lung cancer or any other cancerOliveira2007Individuals admitted in the Pediatric department of the Federal University of Sao Paulo, Brazil without osteosarcomaMustea2007The control group consisted of similarly aged women with no history of cancer and all of them were treated for benign gynecological diseases. None of them had previously undergone a hysterectomyYoon2008Healthy controlPrice2008Healthy controls were frequency matched for age and sex. The controls were healthy nonblood-related family members (usually spouses) and friends of other cancer/surgical patients and were used as a shared set of controls for aerodigestive cancersChoi2008Free of both prostate cancer and lung cancerSaygilii2009Healthy volunteers and No one in the control group had a smoking history or chronic use of any drugsKlinchid2009Healthy volunteers and diabetic patientsWu2010With the same habits and without a present or previous history of any cancerHsieh2010Non-leiomyomaGuo2010Spouse or geographically matched residents who were EBV/IgA/VCA positive (IgA+) or EBV/IgA/ VCA negative (IgA-) and NPC free at the time of study enrollmentNahon2011HCV-induced cirrhosisWang2011Non-cancer controlsLi2011Healthy had no current or previous diagnosis of cancer and genetic diseaseLi2011Diagnosed as normal by histopathology of ophageal squamous epithelial cellsArslan2011Healthy individuals without any history of cancerJang2012Individuals without gastic cancerCarmo2012They had persistent anti-HCV antibodies and were HCVRNA positive. Presence of hepatitis A, hepatitis B, and immunodeficiency virus (HIV) antibodies were considered as exclusion criteriaTefik2013Normal DRE and serum PSA levels of \<4 ng/mLBag2014Normal healthy individuals with no history of cancerKiyohara2014Without a clinical history of any type of cancer past or present, ischemic heart disease or chronic respiratory diseases

Cumulative meta-analysis {#Sec15}
------------------------

We performed cumulative meta-analyses for both overall cancer risk and lung cancer risk. For the former, as was shown in Fig. [3](#Fig3){ref-type="fig"}, the cumulative result of allele contrast showed a declining trend in the estimated protective effect in the vicinity of 0.890 during 2001 and 2014. And the relative change in the random-effects ORs was lower than 1.0 since 2001. Further, the increasingly narrower 95%CIs suggested the precision of the estimates was gradually improved by continually adding more samples. In the same gene model, the inclination toward a non-significant association with overall lung cancer risk except for adding data provided by Heike in 2002 and Isabelle in 2003.Fig. 3Cumulative meta-analysis of MPO-463G \> A polymorphism in association with cancers by published year (A vs. G)

Sensitivity analyses and publication bias {#Sec16}
-----------------------------------------

Each included study was deleted one by one to reflect the influence of the individual data on the pooled ORs, and the corresponding results were not significantly changed. Moreover, there was no influence of publication bias in our study by using Begg's test or Egger's tests.

Discussion {#Sec17}
==========

The current analysis provided the most comprehensive investigation of MPO-463G \> A polymorphism and cancer risk. Sixty studies consisted of 16,858 cases and 21,756 controls gave greater information to explore the association; however, the previous meta-analysis published in 2010 included only 43 studies with 14,171 cancer cases and 17,319 controls. The methodology used for this meta-analysis and the statistical evaluation of the results were well-developed. This meta-analysis demonstrated a new subgroup (digestive system cancer group) to discussed the association between MPO-463G \> A polymorphism and cancer risk in depth. In addition, we further stratified the digestive system cancer and lung cancer group by ethnicity and found some interesting results that the protect effect of MPO-463G \> A polymorphism was only found in Caucasians in lung cancer population and Asians in digestive system cancer population. Furthermore, the cumulative meta-analysis which had not been conducted in previous relevant meta-analysis provided more powerful evidence that the results were reliable. Moreover, NOS was used to evaluate the quality of the studies, and results suggested that all the studies included in the current meta-analysis were high quality.

Contrary to the earlier meta-analysis which indicated that no significant association was found in any genetic model, the current meta-analysis showed evidence that allele A was associated with a reduced cancer risk compared with G allele. Besides, in view of the cumulative analysis results, we intended to draw a conclusion that MPO-463G \> A polymorphism had a protective significance of cancer risk. But when the studies were stratified by cancer type, ethnicity, HWE, and control resource, results differed.

Among all the cancers studied in our meta-analysis, lung cancer was mostly discussed. We were interested to find that the results of three related meta-analyses published in 2013, were not identical with each other. Zhou YY et al. found MPO-463G \> A polymorphism was significantly associated with decreased risk of lung cancer risk in Asians under additive model and recessive model \[[@CR72]\]. Zhou C et al. suggested that in allele frequency and dominant models, when stratified by ethnicity, evidence showed a protect effect in Caucasians, but not in Asians \[[@CR73]\]. While, Yang et al. indicated there was no significant association of both overall and stratified analyses according to ethnicity, source of controls and smoking status \[[@CR74]\]. What is more, another two meta-analyses published in 2014 by Li and Huang et al. \[[@CR75], [@CR76]\], respectively, also got different conclusions. The varied results may have relation with the different search strategies, selection criteria, quality of the original studies and so on. Considering the confusing outcome of the lung cancer, we further calculated the data and tried to come to a convincing conclusion. We considered our results more reliable, for all the studies included were of high quality and we removed the duplicated data provided by Li and Huang et al. \[[@CR75], [@CR76]\]. As described above, the cumulative result provided a more powerful evidence and we intended to draw a conclusion that MPO-463G \> A polymorphism may not be a good predictor of lung cancer both in Caucasians or Asians.

We first conducted a digestive system cancer group in meta-analysis and found significant results in allele frequency and dominant models. When it was divided into digestive tract and digestive gland, results indicated that digestive gland was more closely linked with decreasing cancer risk. Similarly, Samart et al. \[[@CR43]\] even found that A allele and G/A or A/A separately reduced the risk of hepatoblastoma of 50 and 56% in Caucasians. Our analysis demonstrated that A allele and AG/AA had a 0.71-fold cancer risk and 0.67-fold cancer risk separately.

As for breast cancer, though positive result had been published before \[[@CR11]\], whether it had a relationship with high level of MPO-G463 \> A polymorphism stayed confusing. Our result for breast cancer was in line with the result by Chu et al. \[[@CR9]\], suggesting a non-significant association. In addition, giving to the fact the level of MPO-containing neutrophils were high in breast tissue with or without cancer \[[@CR77], [@CR78]\], we tend to believe that MPO-463G \> A polymorphism could not predict breast cancer well. A similar situation was seen in the blood system group, and the current study suggested no significant association between it and MPO-463G \> A polymorphism.

Regarding the source of controls, the results should also be concerned. Only in the hospital population, significant results could be observed. This might reflect influence of health status, gene-gene or gene--environment interactions. Well-matched controls should be included in the future studies. Ethnicity is often one of the sources of heterogeneity. Stratifying the ethnicity, strength was observed in Caucasians and Asians under almost all the genetic models instead of the mix ethnicity group. Meanwhile, no significant association between MPO-463G \> A polymorphism and digestive system cancer for Caucasians or lung cancer for Asians were found in any genetic model. Accordingly, we suggest the main source of heterogeneity is from the ethnicities, source of controls, and different cancer itself. And it may have something to do with age, sex, sample size, ethnic background, gene-gene interaction, environment background, and lifestyle. So it is meaningful to discuss this association more detailed. For example, analyses striated by age, sex, and accumulation of sample size are considerable.

Limited data of digestive system cancer and blood system cancer are one of the deficiencies of our meta-analysis. In addition, gene-gene interactions, environment background, and lifestyle were not well addressed in the meta-analysis for the lack of data. Taking it into consideration, more studies aimed to discuss the relationship of MPO-463G \> A polymorphism and digestive system cancer, blood system cancer or the gene-gene or gene--environment interactions should be conducted to give a more deeper knowledge of this association. Besides, the lack of original information about age also limited our more in-depth research. We hope future researches can provide detailed information about age and then the stratified analysis by age could be done.

Conclusion {#Sec18}
==========

Overall, in cumulative analysis, the stable trend indicated that evidence was sufficient to show the association between MPO-463G \> A polymorphism and cancer risk. MPO-463G \> A polymorphism might have an effect in reducing the risk of digestive system cancer, but might not be a good predictor of lung cancer, breast cancer, and blood system cancers. It was significantly associated with cancer risk both in Caucasians and Asians. But no significant association between MPO-463G \> A polymorphism and Caucasians was found in any genetic model for digestive system cancer and no significant association between MPO-463G \> A polymorphism and Asians was found for lung cancer. More studies exploring the association between MPO-463G \> A polymorphism and digestive and blood system cancer are needed in the future.
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